NCT00088881 2017-05-25Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's LymphomaNational Cancer Institute (NCI)Phase 2 Terminated62 enrolled 8 charts